CD8A and myocardial infarction: Obviously, such a therapeutic strategy could not be used in human MI to limit deleterious post-ischemic cardiac remodeling, but underscores the need for developing an anti-human anti-CD8 mAb that induces full and rapid CD8+ T cell depletion to translate cardiac benefit from animal to human.